Azelast Eye Drops

Quick links to important sections

Azelast Eye Drops

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azelast Eye Drops

Property Description
Active ingredient Azelastine Hydrochloride
Form Ophthalmic Solution (Eye Drops)
Pharmacological class Selective Histamine H1-receptor Antagonist
General purpose Alleviating allergic eye itching
Origin Synthetic (Phthalazinone Derivative)

What Type of Medication is Azelast Eye Drops?

Azelast Eye Drops is a synthetic, single-ingredient, prescription-only medication classified as a selective histamine H1-receptor antagonist for topical ocular administration. The product is formulated as a sterile ophthalmic solution delivered in the form of eye drops. Its fundamental identity is rooted in its active ingredient, azelastine hydrochloride, a phthalazinone derivative of synthetic origin. Azelastine hydrochloride is categorized as a second-generation antihistamine, a key feature that often differentiates it from older compounds. The medication is specifically differentiated by its topical ocular use, contrasting it with oral antihistines, which must be absorbed systemically.

The Purpose of Azelastine's Focused Action

The general therapeutic purpose of Azelast Eye Drops is to provide focused relief from the primary symptoms of eye allergies by directly counteracting the chemical processes of the allergic response. Relief is achieved through its dual-acting mechanism, which involves potent H1-receptor antagonism to block the binding sites for histamine, the key substance that triggers allergic itching. Pharmacological data indicate that this mechanism, along with the drug's mast cell stabilization properties, makes it suitable for managing ocular allergy symptoms. This combination of neutralizing and minimizing the production of chemical agents ensures a rapid and targeted effect, leading to the alleviation of the discomfort that characterizes conditions like allergic conjunctivitis.

What side effects are possible with Azelast Eye Drops?

Possible side effects and safety information

The safety profile for Azelastine Hydrochloride Ophthalmic Solution is primarily characterized by adverse reactions documented in official regulatory documents, classified by frequency and System-Organ Class (SOC).

Officially Documented Adverse Reactions

The most frequently reported local adverse reaction is transient eye burning/stinging. The most common systemic adverse reaction is a bitter taste in the mouth, alongside headache. These effects are typically classified as common, occurring in approximately 1% to 10% of patients in clinical reports. Other common reactions may include temporary blurring, conjunctivitis, eye pain, fatigue, and pharyngitis, as listed under the relevant SOC categories (Eye Disorders, Nervous System Disorders, General Disorders).

Serious Reactions and Safety Constraints

Allergic reactions are documented as a potential, though very rare, adverse event. The product is formally contraindicated in individuals with known or suspected hypersensitivity to any component of the formulation. The preservative in the ophthalmic solution, benzalkonium chloride, is noted in regulatory labels as a component that may be absorbed by soft contact lenses.

Population-Specific Safety Notes

The medication's safety has been established for children 3 years of age and older. For use during pregnancy, it is classified as Category C in US documents; use is justified only if the potential benefit outweighs the potential risk. Due to its excretion into milk in low quantities, some regulators advise that use is not recommended during breastfeeding.

Overdose and Emergency Response

Overdose Manifestations and Risk Profile

The official regulatory profile for Azelast Eye Drops addresses overdose based on the route of exposure. No specific reactions are known following localized ocular overdosage, and systemic reactions are not anticipated with the topical route of administration. The primary risk discussed in regulatory documents pertains to accidental intoxication (such as oral ingestion). In these situations, the expected clinical presentation involves disturbances of the central nervous system (CNS), a manifestation derived from high-dose animal experiments. Population-specific overdose notes (e.g., for pediatric or elderly patients) are not explicitly documented in the official regulatory labels.

Emergency Action and Management

Due to the potential for systemic effects from intoxication, the regulator-mandated instruction is to seek medical help immediately for any suspected overdose or accidental ingestion. The official documentation confirms that there is no known antidote for Azelastine. Therefore, treatment for any resultant symptoms must be strictly symptomatic and supportive. All actions must align with the required emergency response for suspected intoxication.

Therapeutic Uses of Azelast Eye Drops

What Azelast Eye Drops Treats: Main Uses and Benefits

The primary role of Azelast Eye Drops is to provide supportive relief in situations involving allergic eye manifestations, specifically those symptoms related to inflammatory or irritative states. It is commonly used across domains where additional symptomatic support is needed and is considered relevant in contexts marked by increased discomfort or tension during acute or recurrent episodes. The product is used for managing the itching associated with allergic conjunctivitis.

The medication is commonly used across core conditions characterized by periods of heightened symptoms, such as seasonal or perennial allergic conjunctivitis. The symptomatic relief offered helps address the associated cluster of symptoms related to physical discomfort, including symptoms of ocular pruritus (itching), eye redness, tearing, and eyelid swelling.

“It is applied in clinical settings that involve acute or unstable symptom patterns, helping patients cope more steadily with difficult episodes.”

This provides supportive relief that generally helps patients maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Symptom Management for Ocular Conditions

Feature Context of Use
Main Target Symptoms Symptoms of eye itching, redness, tearing, and eyelid swelling.
Common Indications Seasonal Allergic Conjunctivitis (SAC) and Perennial Allergic Conjunctivitis (PAC).
Patient Benefit Supports general well-being and contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. DailyMed: Azelastine Hydrochloride Ophthalmic Solution, USP 0.05%

Eligibility and Restrictions for Use

Azelast Eye Drops eligibility is strictly defined by regulatory guidelines concerning patient demographics and existing health conditions.

The medicine is contraindicated in persons with known or suspected hypersensitivity to azelastine hydrochloride or any of the formulation's excipients.

Age and Physiological Eligibility

Age-Related Eligibility: Established use is permitted for adults. For pediatric patients, safety and effectiveness have not been established below three years of age (US label). European regulators permit use from four years for seasonal allergic conjunctivitis and twelve years for perennial allergic conjunctivitis. Use in older adults is generally allowed, as no overall differences in safety or effectiveness have been observed.

Pregnancy and Lactation: The medicine is not recommended for women who are breastfeeding (EU/UK). During pregnancy, use is permitted only if the potential benefit justifies the potential risk to the fetus.

Condition-Based Restrictions

The product is not intended for the treatment of eye infections. Furthermore, use requires caution for individuals with dry eyes or pre-existing disorders of the cornea due to the excipient benzalkonium chloride. Patients who wear soft contact lenses must remove them prior to instillation, as the preservative may be absorbed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Azelastine Hydrochloride Ophthalmic Solution indicates that the drug’s interaction profile is significantly limited due to minimal systemic exposure following topical ocular administration. After being applied to the eye, the active ingredient's plasma levels are generally in the picogram range, which is considered too low to result in clinically relevant systemic drug interactions.


Documented Interaction Profile

Interaction Type Regulatory Status (Official Documentation)
Drug–Drug Interactions (Systemic) None expected or formally documented.
Metabolic Interactions (e.g., CYP Enzymes) Not relevant. Minimal exposure means studies related to high-dose oral azelastine do not apply.
Food, Alcohol, Herbal Products None known or documented in official labeling.
Contraindicated Combinations None officially listed in the regulatory labeling.

Product-Specific Constraint

The only official restriction related to co-administration involves soft contact lenses. This is a timing constraint necessitated by the eye drops' preservative, benzalkonium chloride.

  • Mandatory Timing Rule: Soft contact lenses must be removed before the eye drops are instilled. To prevent the lenses from absorbing the preservative, they should not be reinserted for at least 10 minutes after the administration of the solution. This is not a drug-drug interaction but a procedural constraint stemming from an excipient.

Mechanism of Action

Azelastine eye drops operate through a dual-action pharmacodynamic mechanism influencing specific physiological signaling pathways in the ocular tissues. This action influences specific regulatory pathways and signal transduction sequences.

Blocking the Histamine Signal: H1-Receptor Antagonism

This primary mechanism focuses on the immediate competitive blockade of the Histamine H1-receptor. By occupying these receptors on target cells, Azelastine prevents the inflammatory mediator, histamine, from binding and initiating its characteristic signaling events. This action inhibits the initiation of histamine-induced signaling for sensory nerve stimulation and localized vasodilation.

Stabilizing Immune Cell Activity: Mediator Release Inhibition

The drug further engages mechanisms that regulate the activity of immune cells, notably mast cells. This stabilization process limits the degranulation of these cells, thereby limiting the release of a cascade of inflammatory substances, including histamine and leukotrienes. The mechanism engages regulatory feedback within targeted pathways to influence overall mediator activity.

Dosage and Administration Information

Azelast Eye Drops is an ophthalmic solution strictly administered via the topical ocular route only, meaning the product is not approved for oral or injectable use. The standardized unit of application is one drop instilled into each affected eye.

Official Dosing and Frequency

This medication is typically used on a twice-daily (b.i.d.) schedule for the management of allergic conjunctivitis in adults and eligible pediatric patients. This fixed-interval frequency establishes the official baseline for use. Dosing recommendations for Azelastine 0.05% may be adjusted; the frequency may be increased up to four times a day (q.i.d.) if deemed necessary.

Administration and Timing Constraints

Official instructions specify administration rules for certain populations. The minimum approved age for treatment initiation varies, starting at 3 years of age and older, and at 4 years and older for seasonal use (or 12 years and older for perennial use).

Procedural adherence includes mandatory steps related to contact lenses. Soft contact lenses must be removed prior to instillation due to the presence of the preservative benzalkonium chloride. A mandatory waiting period of at least 10 to 15 minutes is specified before soft contact lenses may be reinserted. Furthermore, for non-seasonal perennial allergic conjunctivitis, the maximum continuous duration of a course is limited to 6 weeks. If a dose is missed, it should be used as soon as remembered, but must never be doubled to compensate for the skipped application.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azelast Eye Drops

This overview describes the types of clinical evaluations that have been conducted for Azelast Eye Drops, focusing on what outcomes researchers monitored and what areas of study remain incomplete. This information is drawn solely from official regulatory documents and peer-reviewed scientific literature.


Evidence Base for Allergic Conjunctivitis

The primary clinical evaluation for Azelast Eye Drops was studied for allergic eye conditions, commonly known as allergic conjunctivitis. This includes conditions characterized by fluctuating or episodic manifestations, such as both seasonal and perennial eye allergies. The research base includes a foundation of double-blind, placebo-controlled Randomized Controlled Trials (RCTs).

Types of Studies Used for Evaluation

Research was conducted during periods of increased symptom activity to explore short-term symptom changes. This includes environmental studies, as well as trials using the Conjunctival Antigen Challenge (CAC) model, where studies explored how symptoms changed over time immediately after exposure. Comparative studies were also applied in research contexts involving fluctuating or unstable symptoms, evaluating the medication structure against other prescription allergy eye drops available at the time.

Measurement of Study Outcomes

Studies monitored outcomes related to physical discomfort. Researchers primarily measured two main outcomes: scores for ocular pruritus (itching) severity and scores for conjunctival redness severity. These are patient-reported outcomes describing perceived discomfort. For the acute experimental studies, research examined the onset of measured change and the duration of observed change.


Duration of Measured Outcomes and Follow-Up Periods Studied

The evidence derived from the acute experimental research scenarios studies observing responses over defined time intervals. These studies reported measurements of initiation of measured change within minutes and observed that measured outcomes were monitored for durations typically around 8 to 10 hours after a single application.

The core environmental RCTs, used in research exploring short-term symptom changes, had follow-up durations that were limited, typically spanning timeframes from two weeks up to eight weeks of continuous use.


Research Gaps and Uncertainties

The clinical trials research primarily focused on adults with a history of allergic conjunctivitis. However, the medication was also evaluated in pediatric patients down to three years of age and older. Data for certain groups remain insufficient.

As noted, long-term effects are not fully established because follow-up durations were limited to short-term intervals (up to eight weeks). Comparative evidence is limited against the full range of newer prescription ocular allergy treatments. While studies explored some differences with older structures, findings were mixed. Data for certain comparisons remain insufficient.

Key Studies & References

  1. Label: AZELASTINE HYDROCHLORIDE OPHTHALMIC SOLUTION 0.05% solution/ drops (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Azelast Eye Drops (FAQ)

Q: How quickly do people typically notice a difference after using Azelast Eye Drops?

A: Studies examining the onset of effect indicate that the action of the drops in preventing eye itching can begin very rapidly. According to clinical trial data, a measurable change has been observed as quickly as within three minutes after application.

Q: How long does the effect of Azelast Eye Drops usually last?

A: Research and official information report that the measured effect on eye itching lasts for a significant duration following a single application. Specifically, measured outcomes were monitored for approximately eight to ten hours.

Q: What are the ingredients listed in Azelast Eye Drops, besides the active substance?

A: The solution contains the active component, azelastine hydrochloride. The formulation also contains the preservative benzalkonium chloride, along with several other inactive ingredients (excipients) typically listed in the product documents, such as disodium edetate, hypromellose, sorbitol, and sodium hydroxide.

Q: Do official documents specify if the drops must be kept refrigerated?

A: Official guidance specifies that the eye drops should be stored at Controlled Room Temperature. Regulatory information confirms that refrigeration is not typically required, but the drops should be stored upright and protected from heat.

Q: What do patient communities mention about the taste sometimes experienced after using the drops?

A: The most common systemic adverse effect reported in official documents is a bitter taste in the mouth. This is described as occurring when the drops drain from the surface of the eye through the tear duct system into the back of the throat.

Q: Is the active ingredient Azelastine related to any other common allergy medicines?

A: Yes, Azelastine is officially classified as a histamine H1-receptor antagonist. This means it belongs to the same general class of medicines commonly known as antihistamines, which work to block the effects of histamine in the body.

Q: Are there restrictions on driving or operating machinery after using Azelast Eye Drops?

A: Official documents advise caution for activities like driving. Because the drops can potentially cause temporary side effects such as eye irritation or blurring of vision, it is advised to wait until vision is clear and stable before attempting to drive or operate machinery.

Q: Is Azelast Eye Drops the same as a decongestant eye drop?

A: No, Azelast Eye Drops and decongestant drops work differently. Azelastine is an antihistamine and mast cell stabilizer that addresses the underlying allergic reaction, while decongestants work by narrowing blood vessels in the eye to reduce visible redness.

Q: Is it common to feel a mild sting when first using the drops?

A: Transient eye burning or stinging is noted in official safety reports as the most frequently reported local reaction. This effect is generally described as mild and occurred in a significant percentage of patients during clinical reports.

Q: Are official documents clear about using Azelast Eye Drops while breastfeeding?

A: Official information indicates that Azelastine is excreted into human milk in small quantities following ocular use. Due to this finding, regulatory documents state that use during the period of breastfeeding is generally not recommended.

Q: What should be done if someone accidentally swallows Azelast Eye Drops?

A: Official patient information leaflets advise that, in the event the eye drops are accidentally swallowed, medical advice should be sought immediately. This typically involves contacting a doctor or hospital casualty department.

Q: Can Azelast Eye Drops make your eyes feel dry?

A: Official adverse reaction reports list symptoms like eye burning, itching, or dryness as less common side effects. Official documents note that caution may be necessary when using the drops if a person has pre-existing dry eye or corneal conditions, due to the presence of the preservative.

Q: What is the risk profile of Azelast Eye Drops compared to nasal sprays with the same active ingredient?

A: The risk profile of the eye drops is considered low regarding effects outside of the eye. This is because minimal systemic exposure occurs after topical ocular administration; the level of drug in the bloodstream is considered too low to cause clinically relevant systemic issues, unlike oral or high-dose nasal administration.

Q: Has Azelastine been studied for any conditions other than seasonal allergies?

A: The medication is officially indicated for seasonal allergic conjunctivitis. However, some regulatory documents also include an indication for non-seasonal (perennial) allergic conjunctivitis, which is a year-round condition.

Q: What information is available regarding the use of Azelast Eye Drops in the elderly population?

A: Clinical studies have shown that the drops do not appear to cause different side effects or problems in older people compared to younger adults. Official information does not indicate a need for different dosing or safety monitoring for the elderly population.

Q: Can the drops affect how other drugs taken by mouth work?

A: Official regulatory information indicates that no clinically relevant drug-drug interactions are expected or formally documented. This is because the amount of medication absorbed into the body after applying the drops is very small.

Q: Why is the official use limited to allergic eye problems?

A: The official use is limited to treating allergic eye problems because the drug's approval is based on clinical trials. These studies specifically demonstrated its effectiveness and safety for relieving the itching and symptoms associated with allergic conjunctivitis.

Q: Is there a mention in the research of using Azelast Eye Drops before allergy season starts?

A: Yes, some regulatory guidance notes the possibility of prophylactic use. This means that if allergen exposure is anticipated, the product may be used for preventative management before the exposure occurs.

Q: Are there any reported cases of Azelast Eye Drops interacting with alcohol?

A: Official regulatory documents and safety information state that no interactions are known or documented between the eye drops and food, alcohol, or herbal products.

Q: Can Azelast Eye Drops be used for eye irritation not caused by allergies?

A: The medication is specifically indicated only for eye itching related to allergic conjunctivitis. Official labels advise that it should not be used to treat irritation caused by contact lenses or eye infections.

Q: Can Azelast Eye Drops be used for non-allergic conjunctivitis?

A: Regulatory guidance indicates that the drops are not suitable for treating eye infections. Its primary indication is limited to allergic forms of conjunctivitis.

Q: What happens if someone misses a scheduled application of Azelast Eye Drops?

A: Official patient information states that a missed application may be used as soon as it is remembered. However, it is explicitly advised never to take a double dose to make up for the skipped application.

Q: Is it described if Azelast Eye Drops are safe for people with dry eye syndrome?

A: The drops contain the preservative benzalkonium chloride. Due to this component, some official documents note that caution may be necessary for patients with pre-existing conditions such as dry eye or corneal disorders.

Q: What should patients know about the potential for eye redness with Azelast Eye Drops?

A: Eye redness is monitored as a therapeutic outcome in clinical studies, but it is also listed in official adverse reaction reports as an infrequent side effect. This means it has been reported to occur in a small percentage of patients (1% to 10%).

Q: What common household products might interact with Azelast Eye Drops?

A: Official regulatory documents assess interactions with systemic drugs, food, and alcohol, and state that no known interactions are documented. Common household cleaning products or similar items are not typically assessed for ocular drug interactions.

Q: What is the recommended period for discarding the bottle after opening?

A: Official guidance often recommends a specific shelf life once the bottle has been opened. In many cases, it is advised to discard the bottle 28 days after first opening it to help ensure the solution remains sterile and effective.

How should Azelast Eye Drops be stored and disposed of?

How to Store and Dispose of Azelast Eye Drops

Azelastine ophthalmic solution must be stored and handled according to specific regulatory requirements to maintain its integrity and sterility.

Storage Conditions

The medication should be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F), though some packaging allows for storage between 2 C and 25 C. It is mandatory to protect the product from freezing.

For multi-dose containers, the bottle must be stored upright and kept tightly closed when not in use. To prevent contamination, the dropper tip must not touch any surface.

Stability and Disposal

Unit-dose (single-use) containers must be discarded immediately after use. For child safety, the medication must be kept out of the sight and reach of children. Unused, expired, or leftover eye drops must be disposed of in compliance with local environmental and pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Azelast Eye Drops found in:

A-Z Index: